Commenting on the final advice from the European Medicines Agency's (EMA) clinical trial advisory groups, Stephen Whitehead, Chief Executive of the ABPI, said: “I am pleased that the EMA is making good progress on designing its policy on access to clinical trial information and the advisory groups have now published their findings."
"We believe appropriate disclosure of information will support scientific discovery in the years to come but it is crucial that patient confidentiality is protected and the medical research and development model is not undermined by the disclosure of commercially sensitive information. We look forward to participating in the EMA’s consultation process to achieve these aims.”
ABPI Press OfficeTel: +44 (0) 20 7747 1441 or +44 (0) 20 7747 1410Mobile: +44 (0) 7850 312064 or +44 (0) 7808 641811Email: email@example.com
The ABPI represents innovative research-based biopharmaceutical companies, large, medium and small, leading an exciting new era of biosciences in the UK.
Our industry, a major contributor to the economy of the UK, brings life-saving and life-enhancing medicines to patients. Our members supply 90 per cent of all medicines used by the NHS, and are researching and developing over two-thirds of the current medicines pipeline, ensuring that the UK remains at the forefront of helping patients prevent and overcome diseases.
The ABPI is recognised by Government as the industry body negotiating on behalf of the branded pharmaceutical industry, for statutory consultation requirements including the pricing scheme for medicines in the UK.